The potential of adenoviral vaccine vectors with altered antigen presentation capabilities

Research output: Contribution to journal › Review › Research › peer-review

Standard

The potential of adenoviral vaccine vectors with altered antigen presentation capabilities. / Neukirch, Lasse; Fougeroux, Cyrielle; Andersson, Anne Marie Carola; Holst, Peter Johannes.

In: Expert Review of Vaccines, Vol. 19, No. 1, 2020, p. 25-41.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Neukirch, L, Fougeroux, C, Andersson, AMC & Holst, PJ 2020, 'The potential of adenoviral vaccine vectors with altered antigen presentation capabilities', Expert Review of Vaccines, vol. 19, no. 1, pp. 25-41. https://doi.org/10.1080/14760584.2020.1711054

APA

Neukirch, L., Fougeroux, C., Andersson, A. M. C., & Holst, P. J. (2020). The potential of adenoviral vaccine vectors with altered antigen presentation capabilities. Expert Review of Vaccines, 19(1), 25-41. https://doi.org/10.1080/14760584.2020.1711054

Vancouver

Neukirch L, Fougeroux C, Andersson AMC, Holst PJ. The potential of adenoviral vaccine vectors with altered antigen presentation capabilities. Expert Review of Vaccines. 2020;19(1):25-41. https://doi.org/10.1080/14760584.2020.1711054

Author

Neukirch, Lasse ; Fougeroux, Cyrielle ; Andersson, Anne Marie Carola ; Holst, Peter Johannes. / The potential of adenoviral vaccine vectors with altered antigen presentation capabilities. In: Expert Review of Vaccines. 2020 ; Vol. 19, No. 1. pp. 25-41.

Bibtex

@article{6d17d849ad164f28b99980cebf2e5edd,
title = "The potential of adenoviral vaccine vectors with altered antigen presentation capabilities",
abstract = "Introduction: Despite their appeal as vaccine vectors, adenoviral vectors are yet unable to induce protective immune responses against some weakly immunogenic antigens. Additionally, the maximum doses of adenovirus-based vaccines are limited by vector-induced toxicity, causing vector elimination and diminished immune responses against the target antigen. In order to increase immune responses to the transgene, while maintaining a moderate vector dose, new technologies for improved transgene presentation have been developed for adenoviral vaccine vectors. Areas covered: This review provides an overview of different genetic-fusion adjuvants that aim to improve antigen presentation in the context of adenoviral vector-based vaccines. The influence on both T cell and B cell responses are discussed, with a main focus on two technologies: MHC class II-associated invariant chain and virus-like-vaccines. Expert opinion: Different strategies have been tested to improve adenovirus-based vaccinations with varying degrees of success. The reviewed genetic adjuvants were designed to increase antigen processing and MHC presentation, or promote humoral immune responses with an improved conformational antigen display. While none of the introduced technologies is universally applicable, this review shall give an overview to identify potential improvements for future vaccination approaches.",
keywords = "Adenoviral vectors, adjuvants, cancer, endogenous retroviruses, invariant chain, vaccines, virus-like particles, virus-like-vaccines",
author = "Lasse Neukirch and Cyrielle Fougeroux and Andersson, {Anne Marie Carola} and Holst, {Peter Johannes}",
year = "2020",
doi = "10.1080/14760584.2020.1711054",
language = "English",
volume = "19",
pages = "25--41",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Taylor & Francis",
number = "1",

}

RIS

TY - JOUR

T1 - The potential of adenoviral vaccine vectors with altered antigen presentation capabilities

AU - Neukirch, Lasse

AU - Fougeroux, Cyrielle

AU - Andersson, Anne Marie Carola

AU - Holst, Peter Johannes

PY - 2020

Y1 - 2020

N2 - Introduction: Despite their appeal as vaccine vectors, adenoviral vectors are yet unable to induce protective immune responses against some weakly immunogenic antigens. Additionally, the maximum doses of adenovirus-based vaccines are limited by vector-induced toxicity, causing vector elimination and diminished immune responses against the target antigen. In order to increase immune responses to the transgene, while maintaining a moderate vector dose, new technologies for improved transgene presentation have been developed for adenoviral vaccine vectors. Areas covered: This review provides an overview of different genetic-fusion adjuvants that aim to improve antigen presentation in the context of adenoviral vector-based vaccines. The influence on both T cell and B cell responses are discussed, with a main focus on two technologies: MHC class II-associated invariant chain and virus-like-vaccines. Expert opinion: Different strategies have been tested to improve adenovirus-based vaccinations with varying degrees of success. The reviewed genetic adjuvants were designed to increase antigen processing and MHC presentation, or promote humoral immune responses with an improved conformational antigen display. While none of the introduced technologies is universally applicable, this review shall give an overview to identify potential improvements for future vaccination approaches.

AB - Introduction: Despite their appeal as vaccine vectors, adenoviral vectors are yet unable to induce protective immune responses against some weakly immunogenic antigens. Additionally, the maximum doses of adenovirus-based vaccines are limited by vector-induced toxicity, causing vector elimination and diminished immune responses against the target antigen. In order to increase immune responses to the transgene, while maintaining a moderate vector dose, new technologies for improved transgene presentation have been developed for adenoviral vaccine vectors. Areas covered: This review provides an overview of different genetic-fusion adjuvants that aim to improve antigen presentation in the context of adenoviral vector-based vaccines. The influence on both T cell and B cell responses are discussed, with a main focus on two technologies: MHC class II-associated invariant chain and virus-like-vaccines. Expert opinion: Different strategies have been tested to improve adenovirus-based vaccinations with varying degrees of success. The reviewed genetic adjuvants were designed to increase antigen processing and MHC presentation, or promote humoral immune responses with an improved conformational antigen display. While none of the introduced technologies is universally applicable, this review shall give an overview to identify potential improvements for future vaccination approaches.

KW - Adenoviral vectors

KW - adjuvants

KW - cancer

KW - endogenous retroviruses

KW - invariant chain

KW - vaccines

KW - virus-like particles

KW - virus-like-vaccines

U2 - 10.1080/14760584.2020.1711054

DO - 10.1080/14760584.2020.1711054

M3 - Review

C2 - 31889453

AN - SCOPUS:85078475301

VL - 19

SP - 25

EP - 41

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 1

ER -

ID: 235775884